Nephrotoxicity pp 277-283 | Cite as

Mechanisms of Cyclosporin a Nephrotoxicity — Rat to Man

  • Hans Dieperink
  • Henrik Starklint
  • Ejvind Kemp
  • Paul Peter Leyssac


Cyclosporin A (CyA) is a cyclical undecapeptide of fungal origin (1–4), and has been used as an immunosuppressive agent in clinical medicine since 1978 (5, 6), where it has been of prime importance in the improvement of organ transplantation results. CyA’s future role in the treatment of autoimmune disease is now subject to intensive studies. However, the nephrotoxicity of the drug is a major obstacle to its successful use.


Cyclosporin Indomethacin Dextran Gentamicin Hyperglycemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. F. Borel, C. Feurer, H. U. Gubler and H. Stahelin, Biological effects of cyclosporin A: A new antilymphocytic agent, Agents Actions, 6: 468 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    H. Dreyfuss, E. Harri, H. Hofmann, H. Kobel, W. Pache, and H. Tscherter, Cyclosporin A and C, Eur J Appl Microbiol, 3: 125 (1976).CrossRefGoogle Scholar
  3. 3.
    T. J. Petcher, H. P. Weber, and A. Ruegger, Crystal and molecular structure of an iodo-derivate of the cyclic undecapeptide cyclosporin A, Helv chim Acta, 59: 1480 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    K. Hillier, Cyclosporin A, Drugs Future, 4: 567 (1979).Google Scholar
  5. 5.
    R. Y. Calne, D. J. G. White, S. Thiru, D. B. Evans, P. McMaster, D. C. Dunn, G. N. Craddock, B. D. Pentlow, and K. Rolles, Cyclosporin A in patients receiving renal allografts from cadaver donors, Lancet, 2: 1323 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    R. L. Powles, A. J. Barrett, H. Clink, H. E. M. Kay, J. Sloane, and T. J. McElwain, Cyclosporin A for the treatment of graft-versus-host disease in man, Lancet, 2: 1327 (1978).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Y. Calne, Cyclosporin, Nephron, 26: 57 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    A. J. Kostakis, D. J. G. White, and R. Y. Caine, Toxic effects in the use of cyclosporin A in alcoholic solution as an immunosuppressant of rat heart allografts, IRCS surgery transplantation, 5: 243 (1977).Google Scholar
  9. 9.
    R. Y. Caine, D. J. G. White, K. Rolles, D. P. Smith and B. M. Herbertson, Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A: Lancet, 1: 1183 (1978).Google Scholar
  10. 10.
    B. Ryffel, Experimental toxicological studies wiyh cyclosporin A, In: “Cyclosporin A”, D. J. G. White, ed., Elsevier, Amsterdam (1982).Google Scholar
  11. 11.
    B. Ryffel, P. Donatsch, M. Madorin, B. E. Matter, G. Ruttiman, H. Schon, R. Stoll, and J. Wilson, Toxicological evaluation of cyclosporin A, Arch Toxicol, 53: 107 (1983).PubMedGoogle Scholar
  12. 12.
    B. Ryffel, OL 27–400 summary of toxicity data, Sandoz Ltd, Basle, Switzerland (1981).Google Scholar
  13. 13.
    A. S. Tonnesen, R. W. Hamner, and E. J. Weinmann, Cyclosporine and sodium and potassium excretion in the rat, Transplant Proc, 15, suppl. 1: 2730 (1983).Google Scholar
  14. 14.
    H. Dieperink, H. Starklint, P. P. Leyssac, Nephrotoxicity of cyclosporin A — an animal model. A study of the nephrotoxic effect of cyclosporin on overall renal and tubular function in conscious rats, Transplant Proc, 15, suppl. 1: 2736 (1973).Google Scholar
  15. 15.
    B. M. Murray, M. S. Paller, and T. F. Ferris, Effect of cyclosporine administration on renal hemodynamics in conscious rats, Kidney Int, 28: 767 (1985).PubMedCrossRefGoogle Scholar
  16. 16.
    B. A. Sullivan, L. J. Hak, and W. F. Finn, Cyclosporine nephrotoxicity: studies in laboratory animals, Transplant Proc, 14, suppl. 1: 145 (1985).Google Scholar
  17. 17.
    H. H. Dieperink, P. P. Leyssac, H. Starklint, E. Kemp, Nephrotoxicity of cyclosporin A. A lithium-clearance and micropuncture study in rats, Eur J Clin Invest, 16: 69 (1986).PubMedCrossRefGoogle Scholar
  18. 18.
    H. Dieperink, P. P. Leyssac, E. Kemp, D. Steinbruchel, H. Starklint, Glomerulotubular function in cyclosporine A treated rats, Clin Nephrol, 25, suppl. 1: S70 (1986).Google Scholar
  19. 19.
    H. Dieperink, E. Kemp, P. P. Leyssac, H. Starklint, M. Wanscher, J. Nielsen, K. A. Jorgensen, V. Faber, and H. Flachs. Ketoconazole and cyclosporine A: combined effects on rat renal function and on serum and tissue cyclosporine A concentration, Clin Nephrol, 25, suppl. 1: S137 (1986).Google Scholar
  20. 20.
    H. Dieperink, P. P. Leyssac, H. Starklint, K. A. Jorgensen, and E. Kemp, Antagonist capacities of nifedipine, captopril, phenoxybenzamine, prostacyclin and indomethacin on cyclosporin A induced impairment of rat renal function, Eur J Clin Invest, 16: 540 (1986).PubMedCrossRefGoogle Scholar
  21. 21.
    H. Dieperink, P. P. Leyssac, H. Starklint, and E. Kemp, Glomerulotubular function in cyclosporin A treated rats. A lithium clearance, occlusion time/transit time and micropuncture study, Proc Eur Dial Trans Assoc, 21: 853 (1985).Google Scholar
  22. 22.
    H. H. Dieperink, P. P. Leyssac, H. Starklint, E. Kemp, Effects of cyclosporin A, gentamicin and furosemide on rat renal function. A lithium clearance study, Clin Exp Pharm Toxicol, in the press.Google Scholar
  23. 23.
    H. Dieperink, P. P. Leyssac, E. Kemp, H. Starklint, N. E. Frandsen, N. Tvede, J. Moller, P. Buchler Frederiksen, N. Rossing, The nephrotoxicity of cyclosporin A in humans. Effects on glomerular filtration and tubular reabsorption rates, Eur J Clin Invest, in the press.Google Scholar
  24. 24.
    B. M. Murray, and M. S. Paller, Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats, Clin Nephrol: 25, suppl. 1: S37 (1986).Google Scholar
  25. 25.
    J. English, A. Evan, D. Houghton, and W. M. Bennett, Experimental cyclosporine (CSA) nephrotoxicity: evidence for renal vasoconstriction with preservation of tubular function, Clin Res, 34: 594A (1986).Google Scholar
  26. 26.
    H. Xue, R. D. Bukoski, D. A. McCarron, and W. Bennett, Cyclosporine induces contraction in isolated vascular smooth muscle, Fed Proc, 45: 669 (1986).Google Scholar
  27. 27.
    B. D. Myers, J. Ross, L. Newton, J. Luetscher, and M. Perlroth, Cyclosporine-associated chronic nephropathy, N Engl J Med, 311: 699 (1984).PubMedCrossRefGoogle Scholar
  28. 28.
    H. J. Schurek, K. H. Neumann, W. P. Jesinghaus, B. Aeikens, and K. Wonigeit, Influence of cyclosporine A on adaptive hypertrophy after unilateral nephrectomy in the rat, Clin Nephrol, 25, suppl. 1: S144 (1986).Google Scholar
  29. 29.
    H. Siegl, B. Ryffel, R. Petric, P. Shoemaker, A. Muller, P. Donatsch, and M. Mihatsch, Cyclosporine, the renin-angiotensin-aldosteronesystem, and renal adverse reactions, Transplant Proc, 15, suppl. 1: 2719 (1983).Google Scholar
  30. 30.
    N. G. Moss, S. L. Powell, and R. J. Falk, Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats, Proc Natl Acad Sci, 82: 8822 (1985).Google Scholar
  31. 31.
    U. Abildgaard, N. -H. Holstein-Rathlou, and P. P. Leyssac, Effect of renal nerve activity on tubular sodium and water reabsorption in dog kidneys as determined by the lithium clearance method, Acta Physiol Scand, 126: 251 (1986).PubMedCrossRefGoogle Scholar
  32. 32.
    K. H. Gnutzmann, K. Hering, and H. -U. Gutsche, Effect of cyclosporine on the diluting capacity of the rat kidney, Clin Nephrol, 25, suppl. 1: S51 (1986).Google Scholar
  33. 33.
    H. Dieperink, E. Kemp, and H. Starklint, Cyclosporin A in high dosages induces renal interstitial fibrosis in the rat, Transplant Proc, in the press.Google Scholar
  34. 34.
    A. G. Palestine, H. A. Austin, J. E. Balon, T. T. Antonovych, S. G. Sabnis, H. G. Preuss, and R. B. Nussenblatt, Renal histopathologic changes in patients treated with cyclosporine for uveitis, N Engl J Med, 314: 1986.Google Scholar
  35. 35.
    G. Klintmalm, Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment beneficial effects of lower doses early after transplantation, In: “Cyclosporin A nephrotoxicity in human transplant patients”, G. Klintmalm, Huddinge, Sweden, Repro print AB, Stockholm (1984).Google Scholar
  36. 36.
    A. Bergstrand, S. O. Bohman, A. Farnsworth, J. M. Gokel, P. H. Krause, W. Lang, M. J. Mihatsch, B. Oppedal, S. Sell, R. K. Sibley, S. Thiru, R. Verani, A. C. Wallace, H. U. Zollinger, B. Ryffel, G. Thiel, and K. Wonigeit, Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: results of an international workshop, Clin Nephrol, 24: 107 (1985).Google Scholar
  37. 37.
    M. J. Mihatsch, A brief review of histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: Scand J Urol Nephrol, 92, suppl: 95 (1985).Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Hans Dieperink
    • 1
  • Henrik Starklint
    • 1
  • Ejvind Kemp
    • 1
  • Paul Peter Leyssac
    • 1
  1. 1.Laboratory of NephropathologyOdense University HospitalOdense CDenmark

Personalised recommendations